At a glance
ClinicalIndex Comparison RecordN/ACompleted· 100 enrolled
Drug / intervention
ClariFix Devicedevice
Likely dose
Not stated in record
Key inclusion· 4
- ✓Age >21 years
- ✓Moderate to severe rhinorrhea (symptom rating 2-3) AND mild to severe congestion (symptom rating 1-3) with minimum TNSS score of 4, present >6 months
- ✓Documented allergy test within last 10 years or willing to undergo testing
- ✓Failed medical management: intranasal steroids used for minimum 4 weeks without adequate symptom relief
Key exclusion· 11
- ✕Clinically significant anatomic obstruction limiting posterior nasal access (septal deviation, perforation, polyps, sinonasal tumor)
- ✕Prior sinus or nasal surgery significantly altering posterior nasal anatomy
- ✕Active nasal or sinus infection
- ✕Moderate to severe ocular symptoms
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of Safety and Efficacy for the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis
In Brief
A clinical study evaluating ClariFix Device for Chronic Rhinitis. Completed, enrolled 100 participants across 6 sites.
Detailed Summary
A multi-center, prospective, non-randomized, interventional clinical trial to assess the safety and effectiveness of the ClariFix™ device when used to ablate unwanted tissue in the nose of subjects with chronic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Rhinitis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedJun 2017
Primary CompletionJul 2018
Study CompletionApr 2020
TodayJul 2026
First PostedJun 9, 2017
Enrollment StartMar 2, 2017
Primary CompletionJul 31, 2018
Study CompletionApr 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.1 years ago
Interventions
ClariFix Devicedevice
Cryoablation in the nasal passageway using the ClariFix Device